ATE159985T1 - Amplification von humanen mdm2 gen in humanen tumoren - Google Patents

Amplification von humanen mdm2 gen in humanen tumoren

Info

Publication number
ATE159985T1
ATE159985T1 AT93912127T AT93912127T ATE159985T1 AT E159985 T1 ATE159985 T1 AT E159985T1 AT 93912127 T AT93912127 T AT 93912127T AT 93912127 T AT93912127 T AT 93912127T AT E159985 T1 ATE159985 T1 AT E159985T1
Authority
AT
Austria
Prior art keywords
human
gene
amplification
mdm2 gene
tumors
Prior art date
Application number
AT93912127T
Other languages
English (en)
Inventor
Marilee Burrell
David E Hill
Kenneth W Kinzler
Bert Vogelstein
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE159985(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE159985T1 publication Critical patent/ATE159985T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT93912127T 1992-04-07 1993-04-07 Amplification von humanen mdm2 gen in humanen tumoren ATE159985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86784092A 1992-04-07 1992-04-07
US07/903,103 US5411860A (en) 1992-04-07 1992-06-23 Amplification of human MDM2 gene in human tumors

Publications (1)

Publication Number Publication Date
ATE159985T1 true ATE159985T1 (de) 1997-11-15

Family

ID=27128021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93912127T ATE159985T1 (de) 1992-04-07 1993-04-07 Amplification von humanen mdm2 gen in humanen tumoren

Country Status (11)

Country Link
US (14) US5411860A (de)
EP (1) EP0635068B2 (de)
JP (1) JP4381476B2 (de)
AT (1) ATE159985T1 (de)
AU (1) AU681851B2 (de)
CA (1) CA2133306C (de)
DE (1) DE69315068T2 (de)
DK (1) DK0635068T4 (de)
ES (1) ES2110608T5 (de)
GR (1) GR3025961T3 (de)
WO (1) WO1993020238A2 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330892A (en) * 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
CA2149318A1 (en) 1992-11-13 1994-05-26 Manuel Perucho Identification of neoplasms by detection of genetic insertions and deletions
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US6803203B1 (en) 1993-10-06 2004-10-12 Brookhaven Science Associates DNA-PK assay
DE4345249C2 (de) * 1993-11-19 1997-12-11 Deutsches Krebsforsch hdm-2-Fragmente mit Bindungsregionen für hdm-2-spezifische Antikörper
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5702908A (en) * 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
AU721204B2 (en) * 1995-06-07 2000-06-29 Johns Hopkins University, The Antibody detection of mismatch repair proteins
JPH11507829A (ja) * 1995-06-13 1999-07-13 イントロヘーネ ベスローテン フェンノートシャップ Ｍｄｍｘと呼称されるｐ−５３結合タンパク質およびそのタンパク質をコードする配列
FR2738151B1 (fr) * 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
WO1997011367A1 (en) * 1995-09-18 1997-03-27 Novartis Ag ASSAY FOR IDENTIFYING INHIBITORS OF THE INTERACTION BETWEEN PROTEINS p53 AND dm2
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
AU777766B2 (en) * 1996-07-05 2004-10-28 Cancer Research Technology Limited Inhibitors of the interaction between p53 and MDM2
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9620028D0 (en) 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
EP0937258A2 (de) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Humane durch zellstress regulierte mhc class i gene
WO1998037187A1 (fr) * 1997-02-21 1998-08-27 Takara Shuzo Co., Ltd. Genes associes au cancer
WO2000053754A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
GB9708089D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to stabilising substances in cells
US6479285B1 (en) 1997-07-02 2002-11-12 Board Of Regents, The University Of Texas System p53 as a regulator of cell differentiation
US6946447B2 (en) * 1997-08-22 2005-09-20 Hybridon, Inc. MDM2-specific antisense oligonucleotides
US6013786A (en) * 1997-08-22 2000-01-11 Hybridon, Inc. MDM2-specific antisense oligonucleotides
US6418461B1 (en) 1997-10-06 2002-07-09 Mci Communications Corporation Intelligent call switching node in an intelligent distributed network architecture
KR20010031325A (ko) 1997-10-22 2001-04-16 나가야마 오사무 티지에프-베타 저해물질의 스크리닝 방법
US20050121033A1 (en) * 1998-02-25 2005-06-09 Ric Investments, Llc. Respiratory monitoring during gas delivery
US6613750B2 (en) 1998-03-19 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Method of inhibiting cell proliferation using an anti-oncogene protein
US20030203862A1 (en) * 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
JP4743672B2 (ja) 1998-07-13 2011-08-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム アミノリン脂質に対する抗体を用いる癌処置方法
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
AU2192800A (en) * 1998-12-22 2000-07-12 Genentech Inc. Compositions and methods for the treatment of tumor
US6713293B1 (en) 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6372490B1 (en) * 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein
DK1632499T3 (da) * 1999-03-08 2007-10-01 Genentech Inc Gensekvenser amplificeret i tumorer og diagnistiske anvendelser deraf
AU2495200A (en) * 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of tumor
US6046320A (en) * 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of MDMX expression
US7655443B1 (en) * 1999-05-07 2010-02-02 Siemens Healthcare Diagnostics, Inc. Nucleic acid sequencing with simultaneous quantitation
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CA2371434A1 (en) * 1999-06-09 2000-12-14 Genentech, Inc. Compositions and methods for the treatment of tumor
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
US6831155B2 (en) * 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
CN1313334A (zh) * 2000-03-15 2001-09-19 上海博德基因开发有限公司 一种新的多肽——人肉瘤蛋白67和编码这种多肽的多核苷酸
AU4465001A (en) * 2000-03-30 2001-10-15 Nippon Kayaku Kabushiki Kaisha Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
JP2001343389A (ja) * 2000-03-30 2001-12-14 Nippon Kayaku Co Ltd Ｍｄｍ２に対する自己抗体の測定によるがんの検査方法およびその試薬
US7883888B2 (en) * 2000-04-05 2011-02-08 The Research Foundation —The State University of New York Peptides selectively lethal to malignant and transformed mammalian cells
EP1311674A2 (de) * 2000-08-24 2003-05-21 Genentech, Inc. Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
US20040086875A1 (en) * 2001-11-05 2004-05-06 Agee Michele L. Novel proteins and nucleic acids encoding same
DE10109813A1 (de) * 2001-03-01 2002-09-12 Thomas Stanislawski Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
US20020045192A1 (en) * 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7498134B2 (en) * 2002-03-30 2009-03-03 The Trustees Of Columbia University In The City Of New York HAUSP-Mdm2 interaction and uses thereof
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
DK1537146T3 (da) 2002-07-15 2011-04-04 Univ Texas Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
WO2004073615A2 (en) * 2003-02-13 2004-09-02 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
WO2008109433A2 (en) 2007-03-02 2008-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
US7632920B2 (en) 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
BRPI0411526A (pt) 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
US7754424B1 (en) 2003-06-27 2010-07-13 Ryogen Llc Isolated genomic polynucleotide fragments from chromosome 12 that encode human carboxypeptidase M and the human mouse double minute 2 homolog
JP4051327B2 (ja) * 2003-09-19 2008-02-20 新科實業有限公司 垂直磁気記録ヘッドおよびその製造方法、ならびに磁気記録装置
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8147825B2 (en) 2004-01-22 2012-04-03 University Of Miami Topical co-enzyme Q10 formulations and methods of use
WO2005097820A1 (en) * 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides for inhibiting mdm2 function
WO2006037131A2 (en) * 2004-09-28 2006-04-06 Surgical Solutions Llc Suture anchor
AU2007333846B2 (en) 2006-12-14 2014-01-23 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008104000A2 (en) 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR101623985B1 (ko) * 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
EP2614837A1 (de) 2007-11-09 2013-07-17 Affitech Research AS Anti-VEGF-Antikörperzusammensetzungen und Verfahren
EP2224961A1 (de) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen
US20090275519A1 (en) * 2008-02-08 2009-11-05 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
JP2012503025A (ja) 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド 精製されたポリペプチド組成物を調製するための方法
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102510755A (zh) 2009-07-13 2012-06-20 哈佛大学校长及研究员协会 双功能钉接多肽和其用途
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
PL2920197T3 (pl) 2012-09-26 2021-09-13 President And Fellows Of Harvard College Peptydy zszywane blokowane proliną i ich zastosowania
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
CA3085079A1 (en) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
AU2014278005B2 (en) 2013-06-14 2018-11-22 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
MX2017003819A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2019014650A1 (en) * 2017-07-13 2019-01-17 City Of Hope ANTICANCER CONJUGATES OF PEPTIDE COUPLED WITH PHOSPHOROTHIOATE AND METHODS OF USE THEREOF
CA3071105A1 (en) 2017-07-27 2019-01-31 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2019031637A1 (ko) * 2017-08-11 2019-02-14 전남대학교산학협력단 p53-비돌연변이 암에 대한 암 마커 유전자 및 치료제 스크리닝 방법
CN108409839B (zh) * 2018-02-13 2020-08-11 中国人民解放军军事科学院军事医学研究院 一种MDM2与p53相互作用的多肽抑制剂及其应用
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA3127776A1 (en) * 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2021072056A1 (en) * 2019-10-08 2021-04-15 Portage Glasgow Limited P53 peptide disrupters of f0x04:p53 protein binding, variants and conjugates thereof.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
ATE120497T1 (de) * 1988-05-09 1995-04-15 Univ Temple Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression

Also Published As

Publication number Publication date
US5618921A (en) 1997-04-08
US5736338A (en) 1998-04-07
US7402570B2 (en) 2008-07-22
EP0635068A1 (de) 1995-01-25
AU681851B2 (en) 1997-09-11
GR3025961T3 (en) 1998-04-30
US20080305490A1 (en) 2008-12-11
US5550023A (en) 1996-08-27
AU4278893A (en) 1993-11-08
US5756455A (en) 1998-05-26
ES2110608T3 (es) 1998-02-16
US5702903A (en) 1997-12-30
JP4381476B2 (ja) 2009-12-09
DE69315068T2 (de) 1998-04-09
DK0635068T3 (da) 1998-04-20
US5519118A (en) 1996-05-21
US20040170971A1 (en) 2004-09-02
DK0635068T4 (da) 2009-07-20
DE69315068D1 (de) 1997-12-11
EP0635068B2 (de) 2009-04-22
EP0635068B1 (de) 1997-11-05
US6399755B1 (en) 2002-06-04
US5420263A (en) 1995-05-30
US5708136A (en) 1998-01-13
US5858976A (en) 1999-01-12
JPH07505294A (ja) 1995-06-15
CA2133306A1 (en) 1993-10-14
WO1993020238A3 (en) 1993-11-11
CA2133306C (en) 2012-10-02
US5606044A (en) 1997-02-25
US5411860A (en) 1995-05-02
WO1993020238A2 (en) 1993-10-14
ES2110608T5 (es) 2009-08-25

Similar Documents

Publication Publication Date Title
ATE159985T1 (de) Amplification von humanen mdm2 gen in humanen tumoren
CY1107121T1 (el) Ρυθμιση διαφοροποιησης αιματοποιητικων βλαστικων κυτταρων με τη χρηση ανθρωπινων μεσυγχυματικων βλαστικων κυτταρων
KR900700625A (ko) Neu유전자 발현 및 생성물의 탐지
AU2789989A (en) Acylated uridine and cytidine and uses thereof
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
AU9058091A (en) Preparation of nucleic acid samples
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
Tantravahi et al. Evidence for methylation of inactive human rRNA genes in amplified regions
DE3751280D1 (de) Enzyme als landwirtschaftliche chemische Hilfsmittel.
TR199800445A2 (xx) cdc25B geni y�kselticisi, haz�rlan��� ve kullan�m�.
IT1126348B (it) Enzima immobilizzato,procedimenti per la preparazione di detto enzima nonche' procedimento per effettuare una reazione enzimatica
IT8220842A0 (it) Supporto per terreno nutritivo prefabbricato per la determinazione qualitativa e quantitativa di microorganismi.
DK0843731T3 (da) Adenovirusvektorer til genterapi
ATE243741T1 (de) Zufuhr von genprodukten mittels mesangium-zellen
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
IT8919050A0 (it) Procedimento per la introduzione di dna esogeno nelle cellule somatiche e germinali di animali.
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
Klein Burkitt lymphoma—A stalking horse for cancer research?
Orkwiszewski et al. Linkage relationship between the genes for thymidine kinase and galactokinase in different primates
ATE107361T1 (de) Gen des hüllproteins des gurkenmosaikvirus.
FI883255A0 (fi) Maenniskans papillomavirus, typ 41 dess dna och av dna:et kodade protein.
Vogelstein et al. Amplification of human MDM2 gene in human tumors
ATE253646T1 (de) Mono-allelische mutationsanalyse und erkennung von keimbahmmutationen
DK0758342T3 (da) Hidtil ukendt peptidisk aktivt stof og fremstilling heraf
Cerletti et al. Peptide bound flavins and succinic dehydrogenase activity in the brain

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0635068

Country of ref document: EP